GENOMICA Receives Authorization for the Commercialization of its Diagnostic Kits and Instruments in South Korea

Food and Healthcare Press Releases Tuesday November 14, 2017 08:30
MADRID--14 Nov--PRNewswire/InfoQuest

GENOMICA, a leading molecular diagnostics company belonging to the PharmaMar Group (MCE: PHM), has announced that it has received authorization in South Korea for commercializing CLART(R) in vitro diagnostic kits together with the autoclart(R) plus equipment by the competent healthcare authorities (KFDA, for its acronym in English).

(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

This authorization comes after the audit carried out to GENOMICA and after verifying that the company's facilities, the technical documentation and the quality system of the instruments and kits comply with the Korean Good Manufacturing Practices.

"Once we obtained the favorable dictum of the Korean authorities, we initiated the procedures to register the products and instruments. Today, we have sales authorization in South Korea, which is an important milestone for us as it is one of the most demanding accreditation bodies in the world and because it contributes to our expansion in Asia-Pacific ", explains Rosario Cospedal, General Director of GENOMICA.

GENOMICA has reached an agreement with the South Korean diagnostics company AGBIO Diagnostics for the distribution of kits and instruments in this country.
About GENOMICA

GENOMIC is the first Spanish company in Molecular Diagnostics and highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability, automation and the highest quality standards. Our main objective is to maintain leadership in genomics applications within the Spanish market, and to extend internationally our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART(R)

GENOMICA has developed diagnostic tests for human papillomavirus associated with cervical cancer, the diagnosis of viral respiratory diseases, multiple detection of human herpes and enteroviruses, as well as detection of gene regions associated to the determination of human therapy response factors, in particular in the Oncology field.

GENOMICA also provides analysis of DNA, Legal and Forensic Medicine, and Technology Transfer services.
About AGBIO Diagnostics

AGBIO Diagnostics is the company in charge of distributing GENOMICA's kits and instruments in South Korea. This company, established in 1994, is specialized in genetic tests for infectious diseases diagnostics. It manufactures microarrays to detect Enteric Virus, drug resistance of Tubercular Bacillus and sexually transmitted diseases. Its corporate vision consist in relying on the potential of molecular diagnostics as a solid foundation for focusing their efforts on the development of innovative technology.

CONTACTS : Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)
Source: PharmaMar

Latest Press Release

Boehringer Ingelheim has a very successful 2017 financial year

- Sharp increase in net sales to nearly 18.1 billion euros (+15.7 per cent in currency-adjusted terms; +13.9 per cent in euro terms) - Operating income rises significantly to around 3.5 billion euros - Return on net sales of 19.3 per cent - Strengthened...

Merck Receives Patent for CRISPR Technology in China

- Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells - Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards -...

Cell and Gene Therapy Catapult Opens Manufacturing Centre to Accelerate Growth of the Industry in the UK

- Centre will 'bridge the gap' between scientific research and commercialisation of the medicines of the future - Over GBP60 million of Industrial Strategy investment is being used to develop the new centre Today,the Cell and Gene Therapy Catapult's...

Creation of Inceptua Clinical Trial Services Marks New Era for the Company

Inceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including Clinical Trial Services, Medicines...

FDI White Paper and Practical Guide Address the Global Burden of Periodontal Disease

FDI World Dental Federation published two resources - a white paper and a practical guide - as part of its Global Periodontal Health Project (GPHP), which aims to bring attention to periodontal health as a priority area for policy worldwide. (Logo:...

Related Topics